Core Viewpoint - The Hong Kong stock market welcomed three new listings on February 6, including Zhuozheng Medical, which experienced a significant price increase of over 34% at the time of reporting [2][3]. Group 1: Zhuozheng Medical's IPO Performance - Zhuozheng Medical's public offering was oversubscribed by 2730.73 times, with 475,000 shares allocated for public sale, representing approximately 10% of the total shares offered [3]. - The international placement for Zhuozheng Medical was oversubscribed by 5.79 times, with 4.275 million shares allocated, accounting for 90% of the total shares offered [5]. - The final offering price for Zhuozheng Medical was HKD 59.90 per share, raising a net amount of HKD 209 million, with a current share price of HKD 80.40, resulting in a profit of HKD 1,025 per lot [6]. Group 2: Company Overview and Market Position - Zhuozheng Medical is a private healthcare service provider in China, focusing on the mid-to-high-end medical service market, targeting affluent consumers who prefer personalized care [6]. - The company operates 19 medical service institutions in major Chinese cities and has expanded internationally with operations in Singapore and Malaysia [6]. - According to a Frost & Sullivan report, Zhuozheng Medical is the third-largest private mid-to-high-end healthcare service provider in China, holding a market share of 2.0% as of 2024 [8]. Group 3: Financial Performance - Zhuozheng Medical's revenue has shown significant growth, increasing from RMB 473 million in 2022 to RMB 959 million in 2024, with revenue for the first eight months of 2025 reaching RMB 696 million, up from RMB 615 million in the same period of 2024 [8]. - The company achieved profitability in 2024, recording a profit of RMB 83.21 million in the first eight months of 2025 [8].
【IPO追踪】新股市场迎“三箭齐发”！卓正医疗飙升逾34%